Oregon Appeal Could Set National Precedent for Adding Female Orgasmic Disorder to Medical Marijuana Programs

OG article by Anthony Martinelli

December 8, 2025

Disorder (FOD) as a qualifying condition for medical marijuana, potentially setting a national precedent. Petitioner Rebecca Andersson shares her post-hysterectomy FOD recovery via cannabis, backed by a clinical trial showing improved sexual function in cancer survivors. Over ten experts from the U.S. and Europe, including physicians and researchers in sexual medicine and cannabinoids, will testify. Clinical sexologist Suzanne Mulvehill notes this as the first such appeal, emphasizing overlooked women's health. Peer-reviewed studies link cannabis to enhanced orgasm frequency, satisfaction, and ease for women with FOD. Only Illinois and Connecticut approve it medically; six states denied. Advocates plan 2026 petitions for conditions like endometriosis and fibroids. Mulvehill collaborates on California legislation and published reviews on cannabis for female orgasmic function. The case underscores disparities in recognizing sexual health in marijuana programs, with growing evidence supporting efficacy. Success could expand access for millions facing FOD, often post-medical procedures or psychological factors. This hearing amplifies calls for inclusive policies, highlighting cannabis's therapeutic potential beyond pain management. National interest rises as women's concerns gain visibility in cannabinoid research.